Eunyoung Choi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Eunyoung Choi has a total of 147 co-authors. Here are the top co-authors by number of shared publications:
- James R. Goldenring
Section of Surgical Sciences, Vanderbilt University Medical Center, Nashville, TN, United States; Epithelial Biology Center, Vanderbilt University Medical Center, Nashville, TN, United States; Department of Cell and Developmental Biology, Vanderbilt University, Nashville, TN, United States; Nashville VA Medical Center, Nashville, TN, United States
17 shared publications Brianna Caldwell
Department of Surgery and Epithelial Biology Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA
6 shared publicationsChangqing Zhang
Department of Surgery and Epithelial Biology Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA
5 shared publicationsHyuk-Joon Lee
Department of Surgery, Seoul National University College of Medicine, Seoul, Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
4 shared publicationsJimin Min
Epithelial Biology Center, Vanderbilt University Medical Center, Nashville, TN, 37232; Department of Surgery, Vanderbilt University Medical Center, Nashville, TN, 37232
4 shared publicationsBogun Jang
Department of Pathology, Jeju National University College of Medicine, Jeju, Republic of Korea
3 shared publications
Latest Publications
- Open Access
- 11 June 2026
- Published by Elsevier in Cellular and Molecular Gastroenterology and Hepatology
- Vol. 20 (9) , 101831
The American Gastroenterological Association/Funderburg Award in Gastric Cancer: Thirty-Five Years of Advances in Gastric Cancer Research
- 11 June 2026
- Published by Elsevier in Cellular and Molecular Gastroenterology and Hepatology
- Vol. 20 (9) , 101831
Open AccessThe American Gastroenterological Association/Funderburg Award in Gastric Cancer: Thirty-Five Years of Advances in Gastric Cancer Research
- 1 December 2025
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 18 (12) , 721-726
Reprogramming the Course of Precancer with Targeted Therapeutic Intervention: Lessons from Interception in Gastric Preneoplasia
Although the majority of gastric cancer research has focused on the treatment of late-stage tumor masses, intervention at precancerous stages represents a far more amenable strategy to achieve long-term prevention of cancer. In contrast with preventative strategies focusing on lifestyle changes and nutritional alterations, few efforts have evaluated the ability to use short-term therapeutic interventions to reverse precancer and thereby reduce risk for developing cancer. The distinct advantage of this approach lies in the recognition that precancerous lesions are far more homogeneous with fewer, if any, driver mutations that can lead to therapy resistance. Our recent studies have demonstrated that a limited 2- to 4-week course of MEK inhibitor in rodent models, and now in a human phase I trial, reduced intestinal metaplasia and increased normal acid-secreting parietal cells in the gastric mucosa. These findings demonstrate the efficacy of targeting the precancerous metaplasia with limited duration treatments that allow recrudescence of normal gastric lineages. Further progress to bring these approaches to clinical utility will require a major change in the outlook of pharmaceutical companies and physicians for initiatives to target precancer.
- 1 December 2025
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 18 (12) , 721-726
Reprogramming the Course of Precancer with Targeted Therapeutic Intervention: Lessons from Interception in Gastric Preneoplasia
Although the majority of gastric cancer research has focused on the treatment of late-stage tumor masses, intervention at precancerous stages represents a far more amenable strategy to achieve long-term prevention of cancer. In contrast with preventative strategies focusing on lifestyle changes and nutritional alterations, few efforts have evaluated the ability to use short-term therapeutic interventions to reverse precancer and thereby reduce risk for developing cancer. The distinct advantage of this approach lies in the recognition that precancerous lesions are far more homogeneous with fewer, if any, driver mutations that can lead to therapy resistance. Our recent studies have demonstrated that a limited 2- to 4-week course of MEK inhibitor in rodent models, and now in a human phase I trial, reduced intestinal metaplasia and increased normal acid-secreting parietal cells in the gastric mucosa. These findings demonstrate the efficacy of targeting the precancerous metaplasia with limited duration treatments that allow recrudescence of normal gastric lineages. Further progress to bring these approaches to clinical utility will require a major change in the outlook of pharmaceutical companies and physicians for initiatives to target precancer.
- Top Cited PapersOpen Access
Hybrid identity and distinct methylation profiles of incomplete intestinal metaplasia in the stomach
Background Gastric intestinal metaplasia (GIM), particularly the incomplete subtype (Inc IM), is strongly associated with increased gastric cancer (GC) risk. However, its role as a true precursor lesion remains uncertain. Objective We aimed to delineate the molecular identity, differentiation potential and oncogenic relevance of Inc IM. Methods Spatial transcriptomics using a custom lineage-enriched panel was applied to profile GIM and GC tissues. Subtype-specific GIM organoid models were developed for DNA methylation and chromatin accessibility profiling. Single-cell RNA sequencing was performed to evaluate differentiation capacity. Results Spatial transcriptomics revealed that Inc IM potentially originates from the deep antral gland cells and harbours a hybrid transcriptomic signature incorporating gastric, small intestinal and large intestinal lineages across both differentiated and stem/progenitor compartments. DNA methylation profiling of subtype-specific organoids showed that Inc IM exhibits extensive intergenic hypermethylation, resembling native antral mucosa. In contrast, complete subtype was marked by promoter hypermethylation of tumour suppressor genes and displayed a more fully intestinalised epigenetic profile. Organoid models recapitulated subtype-specific traits and demonstrated lineage plasticity. Spatial mapping of GC samples revealed an enrichment of Inc IM-like cells, particularly within microsatellite stable tumours. Approximately 76% of the GCs analysed were linked to GIM, while the remaining (24%) appeared to be associated with deep antral differentiation. Conclusions Inc IM represents a phenotypically unstable and epigenetically deregulated metaplastic state with dual-lineage potential and molecular resemblance to GC. These findings establish Inc IM as a true precursor to GC and underscore the importance of active surveillance and early intervention strategies.
Top Cited PapersOpen AccessHybrid identity and distinct methylation profiles of incomplete intestinal metaplasia in the stomach
Background Gastric intestinal metaplasia (GIM), particularly the incomplete subtype (Inc IM), is strongly associated with increased gastric cancer (GC) risk. However, its role as a true precursor lesion remains uncertain. Objective We aimed to delineate the molecular identity, differentiation potential and oncogenic relevance of Inc IM. Methods Spatial transcriptomics using a custom lineage-enriched panel was applied to profile GIM and GC tissues. Subtype-specific GIM organoid models were developed for DNA methylation and chromatin accessibility profiling. Single-cell RNA sequencing was performed to evaluate differentiation capacity. Results Spatial transcriptomics revealed that Inc IM potentially originates from the deep antral gland cells and harbours a hybrid transcriptomic signature incorporating gastric, small intestinal and large intestinal lineages across both differentiated and stem/progenitor compartments. DNA methylation profiling of subtype-specific organoids showed that Inc IM exhibits extensive intergenic hypermethylation, resembling native antral mucosa. In contrast, complete subtype was marked by promoter hypermethylation of tumour suppressor genes and displayed a more fully intestinalised epigenetic profile. Organoid models recapitulated subtype-specific traits and demonstrated lineage plasticity. Spatial mapping of GC samples revealed an enrichment of Inc IM-like cells, particularly within microsatellite stable tumours. Approximately 76% of the GCs analysed were linked to GIM, while the remaining (24%) appeared to be associated with deep antral differentiation. Conclusions Inc IM represents a phenotypically unstable and epigenetically deregulated metaplastic state with dual-lineage potential and molecular resemblance to GC. These findings establish Inc IM as a true precursor to GC and underscore the importance of active surveillance and early intervention strategies.
- Open Access
- 5 March 2025
- Published by Elsevier in Cellular and Molecular Gastroenterology and Hepatology
- Vol. 19 (6) , 101490
Cortactin Facilitates Malignant Transformation of Dysplastic Cells in Gastric Cancer Development
- 5 March 2025
- Published by Elsevier in Cellular and Molecular Gastroenterology and Hepatology
- Vol. 19 (6) , 101490
Open AccessCortactin Facilitates Malignant Transformation of Dysplastic Cells in Gastric Cancer Development
- Open Access
- 24 January 2024
- Published by Elsevier in Gastroenterology
- Vol. 166 (5) , 772-786.e14
Oncogenic Fatty Acid Metabolism Rewires Energy Supply Chain in Gastric Carcinogenesis
- 24 January 2024
- Published by Elsevier in Gastroenterology
- Vol. 166 (5) , 772-786.e14
Open AccessOncogenic Fatty Acid Metabolism Rewires Energy Supply Chain in Gastric Carcinogenesis
- Open Access
- 4 October 2023
- Published by Elsevier in Gastroenterology
- Vol. 166 (1) , 117-131
Targeting Stem Cells and Dysplastic Features With Dual MEK/ERK and STAT3 Suppression in Gastric Carcinogenesis
- 4 October 2023
- Published by Elsevier in Gastroenterology
- Vol. 166 (1) , 117-131
Open AccessTargeting Stem Cells and Dysplastic Features With Dual MEK/ERK and STAT3 Suppression in Gastric Carcinogenesis
- Open Access
- 11 November 2022
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 54 (11) , 1793-1798
Mouse models of Kras activation in gastric cancer
Gastric cancer has one of the highest incidence rates and is one of the leading causes of cancer-related mortality worldwide. Sequential steps within the carcinogenic process are observed in gastric cancer as well as in pancreatic cancer and colorectal cancer. Kirsten rat sarcoma viral oncogene homolog (KRAS) is the most well-known oncogene and can be constitutively activated by somatic mutations in the gene locus. For over 2 decades, the functions of Kras activation in gastrointestinal (GI) cancers have been studied to elucidate its oncogenic roles during the carcinogenic process. Different approaches have been utilized to generate distinct in vivo models of GI cancer, and a number of mouse models have been established using Kras-inducible systems. In this review, we summarize the genetically engineered mouse models in which Kras is activated with cell-type and/or tissue-type specificity that are utilized for studying carcinogenic processes in gastric cancer as well as pancreatic cancer and colorectal cancer. We also provide a brief description of histological phenotypes and characteristics of those mouse models and the current limitations in the gastric cancer field to be investigated further.
- 11 November 2022
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 54 (11) , 1793-1798
Open AccessMouse models of Kras activation in gastric cancer
Gastric cancer has one of the highest incidence rates and is one of the leading causes of cancer-related mortality worldwide. Sequential steps within the carcinogenic process are observed in gastric cancer as well as in pancreatic cancer and colorectal cancer. Kirsten rat sarcoma viral oncogene homolog (KRAS) is the most well-known oncogene and can be constitutively activated by somatic mutations in the gene locus. For over 2 decades, the functions of Kras activation in gastrointestinal (GI) cancers have been studied to elucidate its oncogenic roles during the carcinogenic process. Different approaches have been utilized to generate distinct in vivo models of GI cancer, and a number of mouse models have been established using Kras-inducible systems. In this review, we summarize the genetically engineered mouse models in which Kras is activated with cell-type and/or tissue-type specificity that are utilized for studying carcinogenic processes in gastric cancer as well as pancreatic cancer and colorectal cancer. We also provide a brief description of histological phenotypes and characteristics of those mouse models and the current limitations in the gastric cancer field to be investigated further.
- Open Access
- 11 June 2022
- Published by Elsevier in Gastroenterology
- Vol. 163 (4) , 875-890
Dysplastic Stem Cell Plasticity Functions as a Driving Force for Neoplastic Transformation of Precancerous Gastric Mucosa
- 11 June 2022
- Published by Elsevier in Gastroenterology
- Vol. 163 (4) , 875-890
Open AccessDysplastic Stem Cell Plasticity Functions as a Driving Force for Neoplastic Transformation of Precancerous Gastric Mucosa
- Open Access
- 5 May 2022
- Published by Elsevier in Cell Stem Cell
- Vol. 29 (5) , 826-839.e9
p57Kip2 imposes the reserve stem cell state of gastric chief cells
- 5 May 2022
- Published by Elsevier in Cell Stem Cell
- Vol. 29 (5) , 826-839.e9
Open Accessp57Kip2 imposes the reserve stem cell state of gastric chief cells